• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Buyouts

CVC acquires Doc Generici from Charterhouse

  • Amedeo Goria
  • Amedeo Goria
  • 14 March 2016
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

CVC Capital Partners has wholly acquired Italian pharmaceutical business Doc Generici from Charterhouse Capital Partners.

The deal saw CVC European Equity Partners VI wholly acquire the company. As part of the deal, Doc Generici CEO Gualtiero Pasquarelli will continue to lead the business. US buyout house Blackstone was also interested in the company, unquote" understands.

Details of the transaction remained undisclosed, but, according to press reports, the business has been valued at between €650-680m. Charterhouse scored a 2.7x money multiple (equating to a 40% IRR) following the sale.

Doc Generici

  • DEAL:

    SBO

  • LOCATION:

    Milan

  • SECTOR:

    Pharmaceuticals

  • FOUNDED:

    1996

  • TURNOVER:

    €168m

  • EBITDA:

    €60m

  • VENDOR:

    Charterhouse Capital Partners

  • RETURNS:

    2.7x, 40% IRR

Debt
Unicredit and HSBC provided debt financing to support the transaction.

Previous funding
In 2013, the Charterhouse Capital Partners IX fund bought Doc Generici in an MBO from pharmaceutical companies Apotez, Chessi Farmaceutici and Zambon. The deal value remained undisclosed, but it was reported to stand at around 2.5x the company's turnover, which reached €131.8m with a €34-44m EBITDA in 2012.

The GP claims the business saw its EBITDA increase by 36% during the investment. According to a source familiar with the situation, the company's leverage ratio decreased from 3.7x at the time of Charterhouse's investment to 1x prior to the exit.

Company
Founded in 1996 and headquartered in Milan, Doc Generici produces generic pharmaceutical products. The business claims to have a 15% market share and a portfolio of 180 generic drug molecules, covering predominantly prescription products, with a particular focus on cardiovascular and gastrointestinal conditions.

According to a source familiar with the situation, the company generated a €168m turnover in 2015, with EBITDA amounting to €60m.

People
CVC Captial Partners – Giampiero Mazza (partner).
Charterhouse Captial Partners – Giuseppe Prestia (partner).
Doc Generici – Gualtiero Pasquarelli (CEO).

Adviser
Equity – Gattai Minoli Agostinelli & Partners (legal); Studio Tributario Associato Facchini Rossi & Soci (tax).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Buyouts
  • Exits
  • Healthcare
  • Southern Europe
  • Italy
  • Secondary buyout
  • CVC Capital Partners
  • Charterhouse Capital Partners

More on Buyouts

Clinical trials and biotechnology
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • Buyouts
  • 04 September 2023
EMEA Public to Private M&A
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • Investments
  • 04 September 2023
HR software solutions providers
Main Capital’s Assessio to be sold to Pollen Street

Recruitment software company tripled in revenue under Main Capital’s ownership

  • Buyouts
  • 25 August 2023
Ice cream
Exponent divests ‘significant' stake in Meadow to Canadian investor

Since 2018, GP has diversified food ingredients company's focus beyond commodity dairy

  • Exits
  • 22 August 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013